Psychotic Disorders: all 1,655 studies
Page 14 of 17. Open to participants first (298), then studies with results posted, then the rest; newest registration first within each.
- Mental Health Related to School Dropout in LuxembourgStatus unknownNCT01354236
- HEalth Promotion Intervention in MEntal Health CareCompletedNCT01336946Not applicable
- Web-Based Weight Management for Individuals With Mental IllnessCompletedNCT01324973Not applicable
- Relationship Between Treatment With Bach´s Flower Remedy and Spiritual Well-Being of People With Common Mental DisorderCompletedNCT01324674Phase 2
- The Topical Niacin Skin Flush Test in First Episode PsychosisTerminatedNCT01324297
- Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With SchizophreniaStatus unknownNCT01324167
- Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective DisorderStatus unknownNCT01320982Phase 3
- Multi-site Communication Deficits in SchizophreniaCompletedNCT01317121
- Forensic Assertive Community Treatment: An Emerging Model of Service DeliveryCompletedNCT01313052Phase 3
- Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic FeaturesTerminatedNCT01310140
- An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With SchizophreniaCompletedNCT01309373
- Adapted Cognitive/Affective Remediation for Cannabis Misuse in SchizophreniaCompletedNCT01292577Phase 1/2
- Raloxifene in Treatment of Schizophrenia and Schizoaffective DisorderStatus unknownNCT01280305Phase 3
- Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant SchizophreniaCompletedNCT01279213Phase 4
- Optimization of Treatment and Management of Schizophrenia in EuropeCompletedNCT01248195Phase 4
- Multi-disciplinary Treatment for Patients Experiencing First Episode of PsychosisCompletedNCT01216891Not applicable
- The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic TherapyStatus unknownNCT01215383
- Optimal Duration of Early Intervention for PsychosisStatus unknownNCT01202357Not applicable
- Effectiveness of Ziprasidone for Patients With SchizophreniaCompletedNCT01198353Phase 4
- Duration of Untreated Psychosis (DUP) and Pathways to Care in NordlandCompletedNCT01196858
- Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset PsychosisCompletedNCT01196286Not applicable
- Reduction of Cardiovascular Risk in Severe Mental IllnessStatus unknownNCT01182012Phase 4
- Cognitive Remediation and Functional Skills Training in SchizophreniaCompletedNCT01175642Early Phase 1
- Impact of Family Psychoeducation on PsychosisStatus unknownNCT01172106Not applicable
- Study of Vitamin D in the Severely Mentally IllCompletedNCT01169142Phase 4
- Efficacy and Safety of Paliperidone ER in First Episode PsychosisCompletedNCT01157585Phase 4
- Efficacy and Safety With Ziprasidone in First-episode PsychosisCompletedNCT01157559Phase 4
- Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in SchizophreniaCompletedNCT01121042Phase 3
- Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to RisperidoneCompletedNCT01119638Phase 4
- Tolerance and Effect of Antipsychotics in Children and Adolescents With PsychosisCompletedNCT01119014Phase 4
- A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective DisorderCompletedNCT01116830Phase 1
- A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective DisorderCompletedNCT01094249Phase 1
- Effect of Varenicline on Cognitive Function in Cigarette Smokers With SchizophreniaCompletedNCT01093365Phase 2
- Factors Association With Poor Physical Function in Older Adults With SchizophreniaCompletedNCT01092598
- Prevention of Weight Gain in Early PsychosesCompletedNCT01075295Not applicable
- Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HClCompletedNCT01074632Phase 1
- Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia PatientsCompletedNCT01043250
- Neuroimaging Studies of Neurophysiological Phenotypes in SchizophreniaCompletedNCT01036568
- Cognitive Skills Training Using Computer for Patients With Severe Mental IllnessCompletedNCT01036282Phase 4
- Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or DepressionCompletedNCT01028196
- Intensive Computerized Brain Training (ICBT) in Youth With Early Onset Psychosis (EOP)CompletedNCT01027962Not applicable
- Efficacy and Safety of Aripiprazole in First Episode PsychosisCompletedNCT01026584Phase 4
- Identifying Predictors of Response to Antipsychotics Using a Treatment AlgorithmStatus unknownNCT01016145Phase 4
- Paternal Psychosis After Baby BornCompletedNCT01011088
- Assessing the Effectiveness of Acceptance and Commitment Therapy for Distress Following PsychosisCompletedNCT01003132Not applicable
- Schizophrenia Treatment Adherence Investigation (STAI)CompletedNCT01001481
- Lifestyle Modification for Weight Loss in SchizophreniaCompletedNCT00990925Not applicable
- A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective DisordersCompletedNCT00986336Phase 1
- Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute PsychiatryStatus unknownNCT00986167Phase 4
- Effects of Delta-9-THC and Iomazenil in Healthy HumansCompletedNCT00982982Early Phase 1
- Medication Adherence in Schizophrenia: Development of a CBT-Based InterventionCompletedNCT00980252Not applicable
- Introduction Seminar About Patient Participation and Treatment Options for Psychiatric Patients on Waiting ListCompletedNCT00967265Not applicable
- D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic SchizophreniaCompletedNCT00960219Phase 2
- Supported Employment in a Swedish ContextStatus unknownNCT00960024Phase 2
- To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal VolunteersCompletedNCT00946491Phase 1
- Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission TomographyCompletedNCT00942981
- Homeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental DisorderCompletedNCT00942097Phase 2/3
- Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic SettingCompletedNCT00932529Phase 4
- Role of Anti-Inflammatory Agents in Patients With SchizophreniaCompletedNCT00929955Phase 1
- Stage-specific Case Management for Early PsychosisCompletedNCT00919620Not applicable
- Polypharmacy in Clozapine-resistant SchizophreniaCompletedNCT00918021Phase 4
- Role of Minocycline in First Episode PsychosisCompletedNCT00916461Phase 1/2
- Extended Specialized Assertive Intervention for First Episode PsychosisCompletedNCT00914238Not applicable
- Quality Project to Evaluate and Validate the FAST-O Rating ScaleCompletedNCT00913731
- Effect of Antipsychotics on Appetite RegulationCompletedNCT00903916
- Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective DisorderWithdrawnNCT00892021Phase 1
- A Shared Decision Making Training for Inpatients With SchizophreniaCompletedNCT00885716Not applicable
- An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)CompletedNCT00878462Phase 2
- Risk Factors for Postpartum PsychosisCompletedNCT00872313
- Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With SchizophreniaCompletedNCT00864825Phase 4
- An Adherence Study of Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective DisorderStatus unknownNCT00861003
- Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in SchizophreniaCompletedNCT00859872Phase 4
- Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset SchizophreniaCompletedNCT00847600Phase 4
- Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)CompletedNCT00844922Phase 2
- Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective DisorderWithdrawnNCT00838227Phase 2
- Effects of Antipsychotic Medications on Energy Intake and ExpenditureCompletedNCT00836251
- Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With SchizophreniaStatus unknownNCT00825045Not applicable
- Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With SchizophreniaCompletedNCT00821600Phase 1
- 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET StudyCompletedNCT00818298Not applicable
- Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI)CompletedNCT00817154Phase 1
- As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release FormulationsCompletedNCT00796185Phase 1
- A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderCompletedNCT00796081Phase 1
- A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineCompletedNCT00791622Phase 1
- Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral TherapyCompletedNCT00791440Not applicable
- A Study of QT and QTc Intervals in Patients Administered Immediate Release PaliperidoneCompletedNCT00791349Phase 1
- Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)CompletedNCT00790517Not applicable
- Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic TreatmentStatus unknownNCT00789022
- Ziprasidone vs Standard Therapy for Agitated Patients in the EDWithdrawnNCT00786318Phase 4
- Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified TreatmentCompletedNCT00783185Phase 1
- A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)CompletedNCT00780585
- Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset SchizophreniaTerminatedNCT00757497Phase 1
- DNA Diagnostics for Minimizing Metabolic Side-Effects of AntipsychoticsStatus unknownNCT00752960
- Quetiapine in the Treatment of Psychotic Depression - a Pilot StudyCompletedNCT00751504Phase 3
- Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With SchizophreniaCompletedNCT00749970
- Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic SubjectsTerminatedNCT00734435Phase 2
- Varenicline Treatment in Alcohol and Nicotine Dependent Patients With SchizophreniaCompletedNCT00727103Phase 4
- A Randomized Controlled Trial of Individual Therapy for First Episode PsychosisStatus unknownNCT00722163Early Phase 1
- Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.CompletedNCT00716755Not applicable
- Anticholinergic Burden in SchizophreniaTerminatedNCT00715377Not applicable
- Impact of Genetic Counseling for Female First Degree Relatives of Individuals With Mental IllnessCompletedNCT00714818Phase 3